SCIG Hizentra denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied SCIG / Hizentra as Duplicate Therapy

Aetna's duplicate-therapy denial for subcutaneous immunoglobulin (SCIG) therapy — such as Hizentra (immune globulin subcutaneous, human) — typically arises when the plan's system detects an overlapping claim for another immunoglobulin product, either intravenous (IVIG) or another subcutaneous formulation. Because immunoglobulin products are a therapeutic class used to treat primary immunodeficiency and certain other conditions, Aetna's utilization-management system may flag concurrent claims as duplicative, even when the clinical situation warrants a transition or the products differ in administration method.

### Why This Denial Is Appealable

A transition from IVIG to SCIG — or between SCIG products — is a recognized, clinically managed process. If you are mid-transition and both products appeared on claims simultaneously during a crossover period, or if the flagged "duplicate" is a prior or discontinued product, the denial is based on an administrative timing artifact rather than a true duplication of therapy. Even where the plan treats the class as equivalent, clinical factors such as tolerability differences, administration method preference documented for patient-specific reasons, or a prescriber's clinical rationale for product selection can support an exception.

### Federal Appeal Framework

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans), you are entitled to a full-and-fair review. File within the deadline printed on your denial notice.
• External review: After an adverse internal decision, request independent external review under ACA §2719, generally within approximately four months of the final internal denial.
• Expedited option: Immunoglobulin therapy supports immune function in primary immunodeficiency; a gap in therapy can be clinically urgent. Request expedited review in writing and have your prescriber document the urgency.

### Concrete Appeal Steps

1. Obtain Aetna's duplicate-therapy policy for immunoglobulin products from the Aetna member portal or by calling the number on your insurance card. 2. Identify the exact product flagged as a duplicate and the date range creating the overlap. 3. Confirm with your pharmacy and prescriber whether any overlap was a planned transition period and have that documented in the chart. 4. Ask your immunologist or prescriber to write a letter explaining the clinical basis for the current product and confirming that the other product is not concurrently in use (or explaining any overlap). 5. Submit the internal appeal with pharmacy records showing dispensing dates and the prescriber's clinical letter.

### Documentation to Gather

• Diagnosis confirmation: Chart notes confirming the underlying diagnosis (e.g., primary immunodeficiency or other approved indication) and the clinical rationale for immunoglobulin therapy.
• Therapy history: Pharmacy records showing dispensing dates for all immunoglobulin products, confirming the timeline and any transition.
• Prescriber clinical letter: A letter documenting why Hizentra specifically was selected for this patient and confirming no true concurrent duplicate is in use.
• Transition documentation (if applicable): Chart notes documenting a planned IVIG-to-SCIG transition, including the rationale.
• Criteria mapping: Copy each requirement from Aetna's duplicate-therapy policy; answer each with the specific chart or pharmacy fact.

### Key Reminder

Aetna's coverage policies for immunoglobulin products describe the specific clinical criteria and documentation requirements that apply. Retrieve the current version of the applicable policy directly from Aetna before preparing your appeal.